Given the potential benefit of inhibiting TNFα9 and NF-κB8 in the treatment of type 2 diabetes, the effect of NF-κB inhibiting sodium salicylate and TNFα inhibiting etanercept was assessed in the DIO/STZ and DIO mouse model. Here, NFKB1 is linked to type 2 diabetes mellitus.